Replacement in oncology research

Descriptif du webinaire

This workshop, co-organized by the Swiss 3RCC and the FC3R, will provide insights into replacement methods within the field of oncology research. Over the course of half a day, seven experts will present their research, emphasizing how in vitro and in silico methods, such as 3D spheroid models, organoids, mathematical models, and artificial intelligence, can significantly enhance our understanding of various types of cancer. They will also discuss how these methodologies and technologies are being employed to develop new treatments.

Workshop speakers:

Dr. Annabelle Ballesta, Institut Curie, Paris
Dr. Ballesta is specialized in mathematical modeling and machine learning for identifying therapeutic targets and optimizing drug combinations in oncology.

Dr. Muriel Cuendet, University of Geneva
Dr. Cuendet focuses on drugs derived from natural products and will share her expertise on using 3D co-culture spheroids to search for antiproliferative compounds against multiple myeloma.

Dr. Laurent Gros, Institut de Recherche en Cancérologie de Montpellier
Dr. Gros is specialized in pancreatic tumors and will discuss the developement of heterotypic 3D spheroid models to study therapeutic combinations.

Dr. Catherine Monnot, Centre de Recherche des Cordeliers, Paris
Dr. Monnot focuses on deciphering the molecular and functional features of renal carcinoma-specific vasculature and will discuss the relevance of microtumors in 3D co-culture.

MSc. Alicia Pliego Mendieta, University of Zurich
Alicia Pliego Mendieta will explain how artificial intelligence is used to predict and validate drug synergies in ex-vivo tumor organoid models derived from patient samples.

Dr. Olivier Preynat-Seauve, University of Geneva
Dr. Preynat-Seauve will present the AirLiwell technology, a unique method for producing standardized organoids in air/liquid interface conditions.

Dr. George Ramzy, University of Geneva
Dr. Ramzy's expertise lies in colorectal cancer, and he will explain how combining methods can lead to personalized treatments.

Intervenant(s)

Retour